Scenesse Treatment May Improve Life Quality for EPP Patients: Study
-
Loading... - Bosman Thomas
- 09 Feb 2023
- 56 Views
- 0 Like
- 0 Comment
Treatment with Scenesse (afamelanotide) — an implantable medicine used to treat people with intolerance to light — can help improve life quality for those with erythropoietic protoporphyria (EPP), making it easier for them to do certain activities, such as going to work or on vacation, a recent study suggests.
The study found that people with EPP in the Netherlands have poorer quality of life scores compared with the general Dutch population. The rare condition affects patients’ ability to travel and do outdoor activities, or even work in an office with a lot of windows.
“This is the first study that reports that treatment can possibly have a positive impact on employment rate,” the researchers wrote, noting that the findings are broadly in line with other data suggesting that Scenesse can ease photosensitivity in people with EPP. Read More…
